HOW SHOULD I USE PANCREATIC ENZYMES IN CHILDREN WITH CYSTIC FIBROSIS AND OTHER CAUSES OF PANCREATIC INSUFFICIENCY?

Mark E. Lowe, Douglas Lindblad

Research output: Chapter in Book/Report/Conference proceedingChapterpeer-review

Abstract

Pancreatic enzyme replacement therapy (PERT) is essential for patients with pancreatic exocrine insufficiency. In children, the most common cause of pancreatic insufficiency is cystic fibrosis (CF) followed by Shwachman-Diamond syndrome (SDS) and chronic pancreatitis (CP). When caring for patients with these diagnoses, the first question we ask is whether they have pancreatic insufficiency. Of patients with CF, 10% to 15% will not have pancreatic insufficiency. Larger fractions of patients with SDS or CP will also not have pancreatic insufficiency. Although it is clear that patients with pancreatic insufficiency should be treated with PERT, there is controversy about treating patients with evidence of pancreatic disease who do not have pancreatic insufficiency even though their pancreatic function may be decreased. We generally do not prescribe PERT to patients without objective evidence of pancreatic insufficiency.

Original languageEnglish
Title of host publicationCurbside Consultation in Pediatric GI
Subtitle of host publication49 Clinical Questions
PublisherCRC Press
Pages139-142
Number of pages4
ISBN (Electronic)9781040143759
ISBN (Print)9781617110146
DOIs
StatePublished - Jan 1 2024

Fingerprint

Dive into the research topics of 'HOW SHOULD I USE PANCREATIC ENZYMES IN CHILDREN WITH CYSTIC FIBROSIS AND OTHER CAUSES OF PANCREATIC INSUFFICIENCY?'. Together they form a unique fingerprint.

Cite this